DeTeRMIA is an R&D project focused on transforming magnetic resonance imaging (MRI) into the most versatile and powerful tool for the diagnosis and prognosis of prostate cancer. The project’s core objective is to accelerate prostate cancer diagnosis through the development of: 1) Next-generation receiver coils to improve signal sensitivity; 2) Advanced MRI technologies enabling ultra-fast image acquisition with higher quality, and 3) AI-based algorithms for image processing, interpretation, and the development of predictive models for clinical outcomes.

The project brings together leading players in imaging and clinical research: General Electric HealthCare España S.A. as coordinator, alongside I3M (Institute for Instrumentation and Molecular Imaging, UPV) and Instituto de Investigación Sanitaria La Fe (ISS La Fe) in Valencia. DeTeRMIA was selected in the ISCIII–CDTI 2023 Joint Call for R&D projects in Personalized Medicine and Advanced Therapies, under Spain’s Recovery, Transformation and Resilience Plan, co-financed by the European Union – NextGenerationEU.